JC virus antibody status underestimates infection rates. - Wikidata - awgldk - TriplyDB

JC virus antibody status underestimates infection rates.

JC virus antibody status underestimates infection rates.

http://www.wikidata.org/entity/Q37079703

about

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathy Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors Viral miRNAs in plasma and urine divulge JC polyomavirus infection.Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection.JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants Opportunistic DNA Recombination With Epstein-Barr Virus at Sites of Control Region Rearrangements Mediating JC Virus Neurovirulence.Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy 5-HT2 receptors facilitate JC polyomavirus entry.First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.Immune surveillance and response to JC virus infection and PML.The human JC polyomavirus (JCPyV): virological background and clinical implications.Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.Progressive multifocal leukoencephalopathy in multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Natalizumab: risk stratification of individual patients with multiple sclerosis.Sorting out the risks in progressive multifocal leukoencephalopathy.A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.Natalizumab treatment of multiple sclerosis: new insights.Polyomavirus detection in multiple sclerosis patients under natalizumab therapy: Profile and frequency of urinary shedding.Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologica Anti-JC virus seroprevalence in a Finnish MS cohort.Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy.Inter- and intralaboratory comparison of JC polyomavirus antibody testing using two different virus-like particle-based assays.JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.Finger pointing to JC virus: a tale of two indexes.Two demyelinating diseases in the brain of a single patient, PML and MS: how to minimize 'one' while treating the 'other'."All the soarings of my mind begin in my blood:" central nervous system complication of Waldenström macroglobulinemia.JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.

P2860

Q26780412-D4A5EE29-590C-436F-B0B7-BD50974FA7BA Q26859307-6134E4AA-00FD-4C6D-82B3-E9CB0F57834A Q28085415-2258EF3F-87EC-4E57-B78F-7421BFBF142D Q34208184-4BD15B74-4A01-407C-AD58-C9EABA0F4699 Q34325718-51596048-0B08-4BDC-945D-A5416DC66DE7 Q34351212-16A19496-D2FC-47AC-92D1-E14008D60AF1 Q34803324-FD4777EF-2ECB-4B28-BD6A-A822DAFD97F6 Q35078693-4274454F-4188-4DC3-B5A2-C5ED7A16C374 Q35157207-64A402F4-A738-4DB2-B84B-A075703B6E8A Q35874385-F435C927-7A7A-474A-BBF5-4775F464BB75 Q36942417-6F6D20D6-C5CA-4108-8250-457572FDF775 Q37336799-95241627-31FB-4287-83F5-5325ED68D3BC Q37588251-1AF52493-8F5C-465A-A764-91F34A200E06 Q37678580-E37EC876-E926-46A6-8C14-F7557D1C6F1E Q38115572-8C8DA97F-C04A-48A8-A681-800C24EEC892 Q38150405-009F541C-B3ED-4492-8FF2-D4F55B1D56E8 Q38153637-2F070B9A-7EE8-4F30-BB07-8AEE07415234 Q38172961-0B67D5A4-3856-48C0-ACEC-31C362C189FF Q38221343-409857B1-CD2B-4CC2-9E87-FC8B025B5FC5 Q38260098-0F9177A1-786B-4268-89E1-E34A319CD5AC Q38268951-1297FFA5-7267-426E-9466-F50F12185E99 Q38815391-E60171C3-C936-42E7-95DF-5440A69E72E2 Q38868240-0B129554-664C-47C5-8035-A2EB19841FDB Q39048568-FA90F912-AC57-4013-8C1C-E1612DD27670 Q39292843-C7A6F8CD-5D11-45E0-93E5-353B729BE904 Q40039520-63B0AD28-51A0-4BA0-AE59-1CA1E56EE500 Q40067748-3AC06A15-9D9B-4393-BF99-C24FAF6BCBA9 Q40565210-5FC866F5-2A53-4F7B-BB1A-9467C0597839 Q40666987-EDDA06D5-92E3-4E44-A274-3367C769CDD9 Q40928069-21FB4FF6-BCA2-4412-BEE4-2882BA6617F8 Q41528675-E7AFA1A3-3497-46D5-914E-5FCBE89D6B59 Q41727049-8BD28AD7-9481-4086-91DB-E597C1A75ED7 Q42204510-4AB09883-6CB3-41A7-81D3-B93B11ABA98B Q42224706-4E20BDB3-2A9F-4AB6-953A-4435F58FE303 Q42256604-5C248770-D7BF-412E-9B83-91A725796520 Q42257800-A1258F49-E591-4DD6-BE61-123871513DFF Q42560354-B0E0721A-B3A4-4D2D-B86D-55DA2CE60496 Q46883059-7A3F529E-1022-4A93-A447-E41AB61BCFB2 Q48159926-EDD9AD21-2F19-4A5C-BEED-7A394D93A015 Q54230581-DBE12FEF-43AA-4A2B-B0A7-4ADED11011B8

P2860

JC virus antibody status underestimates infection rates.

http://www.wikidata.org/entity/Q37079703

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

JC virus antibody status underestimates infection rates.

@en

JC virus antibody status underestimates infection rates.

@nl

type

label

JC virus antibody status underestimates infection rates.

@en

JC virus antibody status underestimates infection rates.

@nl

prefLabel

JC virus antibody status underestimates infection rates.

@en

JC virus antibody status underestimates infection rates.

@nl

P1433

Q37079703-A6E9530E-5480-4E23-BBEA-BCFF420FAEBD

P1476

Q37079703-CA8E67D6-8A51-4C6E-9279-76AF1C206895

P2093

Q37079703-6E6DC6BC-33DD-4F4E-A11D-1F406C3BFACB

Q37079703-6F699F75-4D60-4F30-822D-AA007FE3DC9E

Q37079703-801BAF94-0916-46FD-9534-C90E75C56013

Q37079703-816C1F14-CC65-46B4-A2AE-8DDC3B6600CD

Q37079703-8B84ACBF-4D30-4070-8DC5-7BB71CD4861E

Q37079703-C4B4496D-6FC2-47BD-A1BE-D29BD78B0554

P2860

Q37079703-0476259A-0576-414C-B860-07BFF2977679

Q37079703-1010E3C4-2A5F-403C-A139-02F658B78EBC

Q37079703-1E76BA58-DD03-4AB8-B0FA-B992200414F0

Q37079703-22E15503-838B-4429-B223-7E1289EE09E5

Q37079703-23888D56-3622-49D9-BF68-FA616FD7B294

Q37079703-282BBBBD-57DF-42B5-9E83-0C1CE41CC5E3

Q37079703-31B323F8-05D4-4ADF-8D91-5974A75C9AE8

Q37079703-350D971D-D364-40FF-8172-21451DF9306B

Q37079703-4B09C9C6-EF8D-457D-A687-667E03C43FBB

Q37079703-55C9B411-0F7E-4F96-A53C-2746DDF91924

P304

Q37079703-71AB22A4-E4E1-4755-A091-0FE1BD5EFF0B

P31

Q37079703-AC55EB8F-F55B-4230-A553-896982D77642

P356

Q37079703-FCAEF37C-B487-408C-8C3E-FC95D354F956

P433

Q37079703-5AA613B0-6778-4351-9FFA-069F90F11E9C

P478

Q37079703-20400AC9-8F2F-4FDA-9619-263AF14AD35B

P577

Q37079703-EF5B68CE-6580-4897-BC99-2E445A658131

P698

Q37079703-0703074E-80D2-4590-8467-B2E4120607C0

P921

Q37079703-EF7C8F04-82FC-4D1B-BA40-FE357DF55706

P932

Q37079703-20C5C803-63DE-406E-96B3-4EFC11A280DE

P356

P1433

Annals of Neurology

P1476

JC virus antibody status underestimates infection rates.

@en

P2093

Craig S Miller

http://www.w3.org/2001/XMLSchema#string

Joseph R Berger

http://www.w3.org/2001/XMLSchema#string

Julie Gurwell

http://www.w3.org/2001/XMLSchema#string

Nubia Vega

http://www.w3.org/2001/XMLSchema#string

Robert J Danaher

http://www.w3.org/2001/XMLSchema#string

Sidney A Houff

http://www.w3.org/2001/XMLSchema#string

P2860

HSV-1 DNA in tears and saliva of normal adults

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

The pathogenesis of progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

Documenting the epidemiologic patterns of polyomaviruses in human populations by studying their presence in urban sewage

Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Immune response in progressive multifocal leukoencephalopathy: an overview.

P304

84-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.23893

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23526716

http://www.w3.org/2001/XMLSchema#string

P921

P932

3737275

http://www.w3.org/2001/XMLSchema#string